{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:59:14Z","timestamp":1783382354167,"version":"3.54.6"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Kidney J"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1093\/ckj\/sfv059","type":"journal-article","created":{"date-parts":[[2015,7,17]],"date-time":"2015-07-17T00:50:43Z","timestamp":1437094243000},"page":"632-636","source":"Crossref","is-referenced-by-count":60,"title":["Thrombotic microangiopathy associated with proteasome inhibitors"],"prefix":"10.1093","volume":"8","author":[{"given":"Ahad","family":"Lodhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad U.","family":"Saqlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Suneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,7,16]]},"reference":[{"key":"2015112504224352000_8.5.632.1","doi-asserted-by":"crossref","unstructured":"Tomoda H Omura S . Lactacystin, a proteasome inhibitor: discovery and its application in cell biology. Yakugaku Zasshi 2000; 120: 935\u2013949","DOI":"10.1248\/yakushi1947.120.10_935"},{"key":"2015112504224352000_8.5.632.2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1995.2878"},{"key":"2015112504224352000_8.5.632.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1362"},{"key":"2015112504224352000_8.5.632.4","unstructured":"Adams J Palombella VJ Sausville EA Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615\u20132622"},{"key":"2015112504224352000_8.5.632.5","unstructured":"Teicher BA Ara G Herbst R The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999; 5: 2638\u20132645"},{"key":"2015112504224352000_8.5.632.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"2015112504224352000_8.5.632.7","unstructured":"Carfilzomib. NCI Drug Directory. http:\/\/www.cancer.gov\/drugdictionary\/?CdrID=459751"},{"key":"2015112504224352000_8.5.632.8","unstructured":"FDA approves Kyprolis for some patients with multiple myeloma. 2012 http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm312920.htm (20 July 2012, date last accessed)"},{"key":"2015112504224352000_8.5.632.9","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4086"},{"key":"2015112504224352000_8.5.632.10","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2013.817556"},{"key":"2015112504224352000_8.5.632.11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1950"},{"key":"2015112504224352000_8.5.632.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05188.x"},{"key":"2015112504224352000_8.5.632.13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21414"},{"key":"2015112504224352000_8.5.632.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288"},{"key":"2015112504224352000_8.5.632.15","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.089334"},{"key":"2015112504224352000_8.5.632.16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-425934"},{"key":"2015112504224352000_8.5.632.17","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214531804"},{"key":"2015112504224352000_8.5.632.18","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1397"},{"key":"2015112504224352000_8.5.632.19","unstructured":"Jhaveri KD Chidella S Varghese J Carfilzomib-related acute kidney injury. Clin Adv Hematol Oncol 2013; 11: 604\u2013605"},{"key":"2015112504224352000_8.5.632.20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-15-156"},{"key":"2015112504224352000_8.5.632.21","doi-asserted-by":"crossref","unstructured":"Mehta N Saxena A Niesvizky R . Bortezomib-induced thrombotic thrombocytopaenic purpura. BMJ Case Rep 2012; doi:10.1136\/bcr-2012-006461","DOI":"10.1136\/bcr-2012-006461"},{"key":"2015112504224352000_8.5.632.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2011.02458.x"},{"key":"2015112504224352000_8.5.632.23","doi-asserted-by":"crossref","unstructured":"Salmenniemi U Remes K . Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma. Hematol Rep 2012; 4: e13","DOI":"10.4081\/hr.2012.e13"},{"key":"2015112504224352000_8.5.632.24","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-008-0140-1"},{"key":"2015112504224352000_8.5.632.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707330"},{"key":"2015112504224352000_8.5.632.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2010.09.006"},{"key":"2015112504224352000_8.5.632.27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702849"},{"key":"2015112504224352000_8.5.632.28","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000297998.33418.7e"},{"key":"2015112504224352000_8.5.632.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.06.001"},{"key":"2015112504224352000_8.5.632.30","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10699"},{"key":"2015112504224352000_8.5.632.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1312353"},{"key":"2015112504224352000_8.5.632.32","doi-asserted-by":"crossref","unstructured":"Nester CM Thomas CP . Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? ASH Educ Program Book 2012; 2012: 617\u2013625","DOI":"10.1182\/asheducation.V2012.1.617.3798924"},{"key":"2015112504224352000_8.5.632.33","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.2006.2.3.271"},{"key":"2015112504224352000_8.5.632.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2012.10.002"},{"key":"2015112504224352000_8.5.632.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2014.05.015"},{"key":"2015112504224352000_8.5.632.36","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.00286"},{"key":"2015112504224352000_8.5.632.37","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099962"},{"key":"2015112504224352000_8.5.632.38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2184.2009.00588.x"},{"key":"2015112504224352000_8.5.632.39","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-010-9189-6"},{"key":"2015112504224352000_8.5.632.40","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015872531675"},{"key":"2015112504224352000_8.5.632.41","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-1010"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/8\/5\/632\/1276607\/sfv059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T07:20:57Z","timestamp":1652858457000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article-lookup\/doi\/10.1093\/ckj\/sfv059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,16]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,9,24]]},"published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1093\/ckj\/sfv059"],"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfv059","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,16]]}}}